palbociclib isethionate
Phase 1TerminatedDevelopment Stage
Childhood Choroid Plexus Tumor
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Dec 8, 2014 → Feb 25, 2019
About palbociclib isethionate
palbociclib isethionate is a phase 1 stage product being developed by Brain Biotech for Childhood Choroid Plexus Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT02255461. Target conditions include Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02255461 | Phase 1 | Terminated |
Competing Products
20 competing products in Childhood Choroid Plexus Tumor